NAV

Vosaroxin

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Generic Name
Vosaroxin
DrugBank Accession Number
DB11999
Background

Vosaroxin is under investigation for the treatment of Leukemia, Myeloid, Acute.

Type
Small Molecule
Groups
Investigational
Structure
3D
Similar Structures
Weight
Average: 401.44
Monoisotopic: 401.115775286
Chemical Formula
C18H19N5O4S
Synonyms
  • Voreloxin
  • Vosaroxin
External IDs
  • AG-7352
  • SNS-595
  • SPC-595

Pharmacology

Indication

Not Available

Reduce drug development failure rates
Build, train, & validate machine-learning models
with evidence-based and structured datasets.
See how
Build, train, & validate predictive machine-learning models with structured datasets.
See how
Contraindications & Blackbox Warnings
Prevent Adverse Drug Events Today
Tap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.
Learn more
Avoid life-threatening adverse drug events with our Clinical API
Learn more
Pharmacodynamics

Not Available

Mechanism of action
Not Available
Absorption

Not Available

Volume of distribution

Not Available

Protein binding

Not Available

Metabolism
Not Available
Route of elimination

Not Available

Half-life

Not Available

Clearance

Not Available

Adverse Effects
Improve decision support & research outcomes
With structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!
See the data
Improve decision support & research outcomes with our structured adverse effects data.
See a data sample
Toxicity

Not Available

Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
DrugInteraction
Integrate drug-drug
interactions in your software
AmbroxolThe risk or severity of methemoglobinemia can be increased when Vosaroxin is combined with Ambroxol.
ArticaineThe risk or severity of methemoglobinemia can be increased when Vosaroxin is combined with Articaine.
BenzocaineThe risk or severity of methemoglobinemia can be increased when Vosaroxin is combined with Benzocaine.
Benzyl alcoholThe risk or severity of methemoglobinemia can be increased when Vosaroxin is combined with Benzyl alcohol.
BupivacaineThe risk or severity of methemoglobinemia can be increased when Vosaroxin is combined with Bupivacaine.
ButacaineThe risk or severity of methemoglobinemia can be increased when Vosaroxin is combined with Butacaine.
ButambenThe risk or severity of methemoglobinemia can be increased when Vosaroxin is combined with Butamben.
CapsaicinThe risk or severity of methemoglobinemia can be increased when Vosaroxin is combined with Capsaicin.
ChloroprocaineThe risk or severity of methemoglobinemia can be increased when Vosaroxin is combined with Chloroprocaine.
CinchocaineThe risk or severity of methemoglobinemia can be increased when Vosaroxin is combined with Cinchocaine.
Identify potential medication risks
Easily compare up to 40 drugs with our drug interaction checker.
Get severity rating, description, and management advice.
Learn more
Food Interactions
Not Available

Categories

ATC Codes
L01XX53 — Vosaroxin
Drug Categories
Chemical TaxonomyProvided by Classyfire
Description
This compound belongs to the class of organic compounds known as naphthyridine carboxylic acids and derivatives. These are compounds containing a naphthyridine moiety, where one of the ring atoms bears a carboxylic acid group.
Kingdom
Organic compounds
Super Class
Organoheterocyclic compounds
Class
Diazanaphthalenes
Sub Class
Naphthyridines
Direct Parent
Naphthyridine carboxylic acids and derivatives
Alternative Parents
Pyridinecarboxylic acids / Dialkylarylamines / Aminopyridines and derivatives / Imidolactams / Vinylogous amides / Thiazoles / Pyrrolidines / Heteroaromatic compounds / Amino acids / Dialkylamines
show 5 more
Substituents
Amine / Amino acid / Amino acid or derivatives / Aminopyridine / Aromatic heteropolycyclic compound / Azacycle / Azole / Carboxylic acid / Carboxylic acid derivative / Dialkyl ether
show 19 more
Molecular Framework
Aromatic heteropolycyclic compounds
External Descriptors
Not Available
Affected organisms
Not Available

Chemical Identifiers

UNII
K6A90IIZ19
CAS number
175414-77-4
InChI Key
XZAFZXJXZHRNAQ-STQMWFEESA-N
InChI
InChI=1S/C18H19N5O4S/c1-19-12-8-22(9-13(12)27-2)14-4-3-10-15(24)11(17(25)26)7-23(16(10)21-14)18-20-5-6-28-18/h3-7,12-13,19H,8-9H2,1-2H3,(H,25,26)/t12-,13-/m0/s1
IUPAC Name
7-[(3S,4S)-3-methoxy-4-(methylamino)pyrrolidin-1-yl]-4-oxo-1-(1,3-thiazol-2-yl)-1,4-dihydro-1,8-naphthyridine-3-carboxylic acid
SMILES
CN[C@H]1CN(C[C@@H]1OC)C1=CC=C2C(=O)C(=CN(C3=NC=CS3)C2=N1)C(O)=O

References

General References
Not Available
PubChem Compound
9952884
PubChem Substance
347828318
ChemSpider
8128494
ChEMBL
CHEMBL68117
ZINC
ZINC000026186622
Wikipedia
Vosaroxin

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
3CompletedTreatmentAcute Myeloid Leukemia1
2Active Not RecruitingTreatmentAcute Myeloid Leukemia / Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome / Acute Myeloid Leukemia With Multilineage Dysplasia / Granulocytic Sarcoma / Secondary Acute Myeloid Leukemia (Secondary AML, sAML) / Therapy-Related Myelodysplastic Syndrome / Treatment-Related Acute Myeloid Leukemia1
2CompletedTreatmentAcute Disease / Acute Myeloid Leukemia / Leukemias / Myelodysplastic Syndrome / Nonlymphocytic Leukemia1
2CompletedTreatmentAcute Myeloid Leukemia / Myelodysplastic Syndrome With Excess Blasts-2 (MDS-EB-2)1
2CompletedTreatmentEpithelial Ovarian Cancer1
2CompletedTreatmentNon-Small Cell Lung Carcinoma1
2CompletedTreatmentSmall Cell Carcinoma / Small Cell Lung Cancer (SCLC)1
2, 3RecruitingTreatmentAcute Myeloid Leukemia1
2, 3Unknown StatusTreatmentAcute Myeloid Leukemia / Myelodysplastic Syndrome1
1Active Not RecruitingTreatmentMyelodysplastic Syndrome1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.128 mg/mLALOGPS
logP-0.49ALOGPS
logP-0.42Chemaxon
logS-3.5ALOGPS
pKa (Strongest Acidic)5.06Chemaxon
pKa (Strongest Basic)8.8Chemaxon
Physiological Charge0Chemaxon
Hydrogen Acceptor Count9Chemaxon
Hydrogen Donor Count2Chemaxon
Polar Surface Area107.89 Å2Chemaxon
Rotatable Bond Count5Chemaxon
Refractivity103 m3·mol-1Chemaxon
Polarizability41.3 Å3Chemaxon
Number of Rings4Chemaxon
Bioavailability1Chemaxon
Rule of FiveYesChemaxon
Ghose FilterNoChemaxon
Veber's RuleNoChemaxon
MDDR-like RuleNoChemaxon
Predicted ADMET Features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available

Drug created at October 20, 2016 21:09 / Updated at January 14, 2023 19:03